WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer

Inclusion Criteria: * Histologically confirmed diagnosis of oral, laryngeal or hypopharyngeal squamous cell carcinoma * Multi-Disciplinary Team (MDT) recommendation for surgical resection with curative intent * Eastern Cooperative Oncology Group (ECOG) performance status 0/1 * Age ≥18 to ≤70 years * Creatinine clearance, measured by Glomerular Filtration Rate (GFR), ≥ 60 ml/min at baseline calculated using local practice calculation. If this is ≤ 60 ml/min then an isotopic GFR may be carried out and must be \> 60 ml/min * Acceptable cardiac function. If significant cardiac history, then required for patient to have Left Ventricular Ejection Fraction (LVEF) ≥55% by echocardiogram (ECHO) or Multiple Gated Acquisition Scan (MUGA, if ECHO is equivocal) * Normal liver and bone marrow function: * Haemoglobin (Hb) ≥10.0 g/dL or ≥100 g/L * Absolute neutrophil count (ANC) ≥1.5 x 109/L * Absolute platelet count ≥100 x 109/L * Aspartate transaminase (AST) or alanine aminotransferase (ALT) ≤2.5 upper limit of normal (ULN) * Total bilirubin ≤1.5 ULN (except for patients with known Gilbert's syndrome) * Male and female participants must agree to take appropriate measures to prevent pregnancy. Contraceptive measures should be used for 2 weeks prior to trial entry, during the trial and for at least 6 months after last receiving treatment. Acceptable methods of contraception include total abstinence (if this is the patient's usual and preferred lifestyle choice), tubal ligation, c…